In our previous report, we demonstrated that either genetic deficiency of IFNγR signaling or pharmacologic inhibition of its downstream targets JAK1 and JAK2 using INCB018424 results in less GvHD after allo-HSCT by reducing alloreactive T cell trafficking to GvHD target organs [3]. This evidence concerns the gene JAK2 and graft versus host disease.